Literature DB >> 21835356

II. Cerebral infarction/transient ischemic attack (TIA).

Yukito Shinohara1, Takehiko Yanagihara, Koji Abe, Toshiki Yoshimine, Toshiyuki Fujinaka, Takayo Chuma, Fumio Ochi, Masao Nagayama, Akira Ogawa, Norihiro Suzuki, Yasuo Katayama, Akio Kimura, Kazuo Minematsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21835356     DOI： 10.1016/j.jstrokecerebrovasdis.2011.05.004

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN： 1052-3057            Impact factor:   2.136


× No keyword cloud information.
  14 in total

Review 1.  Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.

Authors:  David J Seiffge; David J Werring; Maurizio Paciaroni; Jesse Dawson; Steven Warach; Truman J Milling; Stefan T Engelter; Urs Fischer; Bo Norrving
Journal:  Lancet Neurol       Date:  2018-11-08       Impact factor: 44.182

2.  Plasma Homocysteine Levels Predict the Risk of Acute Cerebral Infarction in Patients with Carotid Artery Lesions.

Authors:  Wei Wu; Yi Guan; Kan Xu; Xi-Jia Fu; Xiao-Feng Lei; Li-Jian Lei; Zhi-Qing Zhang; Yan Cheng; Yun-Qian Li
Journal:  Mol Neurobiol       Date:  2015-06-11       Impact factor: 5.590

3.  Bias in the use of randomized trials for carotid stenosis management.

Authors:  A L Abbott
Journal:  Gefasschirurgie       Date:  2015

4.  Effectiveness of Hospital Functions for Acute Ischemic Stroke Treatment on In-Hospital Mortality: Results From a Nationwide Survey in Japan.

Authors:  Tetsuya Iwamoto; Hideki Hashimoto; Hiromasa Horiguchi; Hideo Yasunaga
Journal:  J Epidemiol       Date:  2015-07-11       Impact factor: 3.211

5.  Intravenous tissue plasminogen activator for an ischemic stroke with occult double primary cancer.

Authors:  Yukihiro Yoneda; Akira Fukuda; Tomohiro Yamazaki; Natsuhi Sasaki; Masahiko Ohta; Yasufumi Kageyama
Journal:  Case Rep Neurol       Date:  2014-10-29

6.  Quality Improvement in Acute Ischemic Stroke Care in Taiwan: The Breakthrough Collaborative in Stroke.

Authors:  Fang-I Hsieh; Jiann-Shing Jeng; Chang-Ming Chern; Tsong-Hai Lee; Sung-Chun Tang; Li-Kai Tsai; Hsun-Hsiang Liao; Hang Chang; Kenneth A LaBresh; Hung-Jung Lin; Hung-Yi Chiou; Hou-Chang Chiu; Li-Ming Lien
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

7.  Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial.

Authors:  Jie Xu; Yilong Wang; Anxin Wang; Zhiqiang Gao; Xiaoping Gao; Huisheng Chen; Junshan Zhou; Xingquan Zhao; Yongjun Wang
Journal:  Stroke Vasc Neurol       Date:  2019-04-22

Review 8.  Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis.

Authors:  Teruyuki Hirano
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-09-15       Impact factor: 1.742

9.  Association of geographical factors with administration of tissue plasminogen activator for acute ischemic stroke.

Authors:  Susumu Kunisawa; Toshitaka Morishima; Naoto Ukawa; Hiroshi Ikai; Tetsuya Otsubo; Koichi B Ishikawa; Chiaki Yokota; Kazuo Minematsu; Kiyohide Fushimi; Yuichi Imanaka
Journal:  J Am Heart Assoc       Date:  2013-09-17       Impact factor: 5.501

10.  Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis.

Authors:  Luda Feng; Ning Liang; Tingting Li; Qinyu Yang; Ping Jiang; Shengnan Guo; Chi Zhang; Ying Gao
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.